Clinical trials: Nerve Condition
Cancer of Bladder
Comparison of Obturator Nerve Blockade and Neuromuscular Blockade
Patients diagnosed with posterolateral bladder tumors will be invited to participate in the study. Subjects will be randomized to receive an ultrasound-guided obturator block or a neuromuscular blocking agent after the induction…
- Trial name
- NCT03063255
- Testing
- Obturator block, Neuromuscular block
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma
- Trial name
- NCT03213678
- Testing
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Melanoma
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b…
- Trial name
- NCT02089685
- Testing
- Pembrolizumab, PegIFN-2b, Ipilimumab
- Volunteers
- 295 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Advanced Melanoma, Metastatic Melanoma
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced…
- Trial name
- PD-1 (NCT01621490)
- Testing
- Nivolumab, Ipilimumab
- Where
- 14 sites in United States, Netherlands and 1 more
- Volunteers
- 170 people
- Sponsor
- Bristol-Myers Squibb
Leber's Congenital Amaurosis
Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
- Trial name
- NCT03140969
- Testing
- QR-110
- Where
- 3 sites in United States, Belgium
- Volunteers
- 11 people
- Sponsor
- Laboratoires Thea
Glioblastoma
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent…
- Trial name
- NCT03149003
- Testing
- DSP-7888 Dosing Emulsion, Bevacizumab
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- Sumitomo Pharma America, Inc.
Breast Cancer, Iron Overload
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant.
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma
- Trial name
- NCT00602446
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Normal Tension Glaucoma, Ocular Hypertension
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.
- Trial name
- NCT01995136
- Testing
- Travoprost Ophthalmic Solution 0.004%
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Alcon Research
Brain and Central Nervous System Tumors
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00869401
- Testing
- dasatinib, temozolomide, radiation therapy
- Where
- 207 sites in United States
- Volunteers
- 217 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Unexplained Nausea and Vomiting, Gastroparesis
Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
The hypothesis of this pilot study is that nVNS will result in relief of nausea by modulation of vagal nerve activity. nVNS is the first non-invasive, handheld medical device applied on the side of the neck and sends gentle…
- Trial name
- nVNS (NCT04857281)
- Testing
- nVNS (gammaCore)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Johns Hopkins University
Melanoma (Skin), Squamous Cell Carcinoma
Using MC1R Genotype to Impact Melanoma Risk Behavior
The purpose of this study is to examine how different messages about risk of melanoma can impact the way people protect themselves against developing these diseases.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma, Squamous Cell Cancer, Skin Cancer
- Trial name
- NCT03509467
- Testing
- Personalized Information, Standard Information, DNA Extraction Determination of MC1R Genotypes
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 2,054 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
PostTraumatic Stress Disorder
Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder
The tasks of the project are to map the potency and kinetics of the neurologic, autonomic peripheral, inflammatory, and behavioral responses to vagal nerve stimulation (VNS) vs.
- Trial name
- NCT02992899
- Testing
- GammaCore/electroCore non-invasive VNS device, O-15 water
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Emory University
Malignant Melanoma
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete…
- Trial name
- NCT01636960
- Testing
- PegIFN alfa-2b
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Uveal Melanoma
Treatment With Intravitreal Avastin for Large Uveal Melanomas
The purpose of this study is to test the safety and effectiveness of Avastin introduced into the inside of the eyeball in causing shrinkage of the uveal melanoma (tumor of the eye).
- Trial name
- NCT00596362
- Testing
- AVASTIN
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.